RT @AmyPearlman1: I loved loved loved giving a recap of our work over the last year with @DaynaSmerina . 🙏 @UrologyTimes for allowing curio…

RT @ASCO: The #GU25 abstracts are now available! Late-Breaking Abstracts (LBAs) will be released at 7:00 AM PT on their day of presentation…

RT @DrChoueiri: The #GU25 abstracts are out! @ASCO @JCO_ASCO @ReneeSaliby @yekeduz_emre @MikeSerzanMD @enriqueigl…

RT @Adam_Weiner535: 💡Really looking forward to taking over @UrologyTimes to report on some of the biggest works coming out of #GU25 for #p…

@Adam_Weiner535 @hannahclarke722 We can't wait! ⭐️

RT @UrologyTimes: @Adam_Weiner535 will be taking over our account on Thursday 2/13 during #GU25. Throughout the day, Dr. Weiner will share…

@Adam_Weiner535 will be taking over our account on Thursday 2/13 during #GU25. Throughout the day, Dr. Weiner will share his take on key data presented as well as session updates, photos with colleagues, and other notable updates. Stay tuned! @CedarsSinai + @UclaUrology @ASCO

Dayna R. Smerina (@DaynaSmerina) and Amy M. Pearlman, MD, (@AmyPearlman1) discuss their research projects in sexual medicine.

Nedim Ruhotina, MD, outlines currently available as well as promising up-and-coming biomarkers for advanced prostate cancer. #pcsm

The #FDA has granted 510(k) clearance to Ibex Prostate Detect, an AI-powered digital pathology tool designed to detect prostatic cancers that may have been overlooked on the first diagnostic assessment.

Channing J. Paller, MD, (@Cpaller) discusses how health care professionals can best communicate the potential benefits and risks of natural products for prostate cancer to both patients and fellow health care professionals. @brady_urology #pcsm

Mark D. Tyson, II, MD, MPH, (@MarkTysonMD) discusses the impact of gene therapy and advancements in BCG-unresponsive NMIBC treatment. @MayoUrology

#ICYMI: Take a look through our recap of the FDA submissions and regulatory decisions in #urology from January 2025.

RT @DrDeanElterman: @UrologyTimes highlights tailoring #BPH care with new #MIST and latest #FIT #FirstlineInterventionalTherapy (recently i…

Dean S. Elterman, MD, MSc, FRCSC, (@DrDeanElterman) gives an overview of his #DSUIOnTheBeach25 talk, "Tailoring MIST therapies in BPH for the individual." @dsui_miami_uro

"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD. @alantanmd @VUMCurology @VUMC_Cancer #kcsm

Vanita Gaglani, RPT, discusses her books on post-prostatectomy incontinence and prostatitis. #urology

Data from the pivotal OASIS trial have been published in the Journal of Urology, showing that efficacy of the Revi System for #UUI was maintained at 2 years. #urology

Mark D. Tyson, MD, MPH, (@MarkTysonMD) and Gary D. Steinberg, MD, (@garysteinbergmd) discuss recent FDA approvals in NMIBC. #blcsm

Amar Kishan, MD, (@AmarUKishan) touches on the implications of findings from the MIRAGE trial, which showed that aggressive margin reduction with MRI-guided SBRT reduced short- and long-term toxicity vs CT-guided SBRT. @UclaUrology #pcsm